EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...

Welcome to the Starbucks inside CIA headquarters—known officially in hushed tones as “Store Number 1.” It is affectionately ...

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of two tissue ...

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly ...

LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / Avant Technologies Inc. (OTCQB:AVAI) (“Avant” or the “Company”), and its ...

The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ABCA4-associated ...

Jacksonville Lions Club and Lions of Illinois Foundation will offer free hearing and retinal screenings in Jacksonville.

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...

The FDA grants RPDD for serious and life-threatening diseases that primarily affect children ages 18 years or younger and fewer than 200,000 people in the U.S. There are approximately 100,000 people ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.